Introduction. Trabectedin treatment in GYN cancers

Int J Gynecol Cancer. 2011 May;21 Suppl 1:S1-2. doi: 10.1097/IGC.0b013e318217b337.

Abstract

Ovarian cancer is the second most common gynecological cancer, representing 5% of all cancers in women. It has the highest case-fatality rate of all gynecological malignancies. In the European Union, there are approximately 48,000 new cases of ovarian cancer and 31,000 deaths per year. Similarly, in the United States, there are approximately 25,500 new cases per year, with 16,000 deaths associated.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Dioxoles / therapeutic use*
  • Female
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Tetrahydroisoquinolines / therapeutic use*
  • Trabectedin
  • Urochordata

Substances

  • Antineoplastic Agents, Alkylating
  • Dioxoles
  • Tetrahydroisoquinolines
  • Trabectedin